Stock Track | Repligen Plunges 5.48% in Pre-market on Weak FY26 Earnings Guidance

Stock Track
Feb 24

Repligen's stock experienced a significant pre-market plunge of 5.48% on Tuesday, following the release of the company's fourth quarter 2025 financial results and 2026 guidance.

The biotechnology tools company reported better-than-expected Q4 results, with adjusted earnings per share of $0.49 beating the consensus estimate of $0.44, and revenue of $198 million surpassing the expected $192.9 million. However, investors reacted negatively to the company's fiscal 2026 outlook.

Repligen provided full-year 2026 earnings guidance of $1.93 to $2.01 per share, which fell short of the analyst consensus estimate of $2.07 per share. The company's revenue guidance of $810 million to $840 million was roughly in line with consensus expectations of approximately $823.87 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10